Treatment for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new combination of chemotherapy drugs for people with nasopharyngeal cancer that has spread or come back. The goal is to see if it can help control the cancer and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have nasopharyngeal cancer that has spread to other parts of the body or come back after treatment.
- Your cancer is not suitable for local treatments like surgery or radiation.
- You have at least one tumor that can be measured on a scan.
- Your vital organs (like bone marrow, liver, and kidneys) are working well enough.
- You are expected to live at least 3 more months.
- You have not had any allergies to the chemotherapy drugs used in this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests whether combining a newer chemotherapy drug (lobaplatin) with standard radiation and chemotherapy is safe and effective for adults aged 65 to 80 with a certain type of nasopharyngeal cancer that hasn't spread to distant organs.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.